This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gijsman, H. J. Articles by Van Gerven, J. M. A Search for Related Content PubMed PubMed Citation Articles by Gijsman, H. J. Articles by Van Gerven, J. M. A Social Bookmarking                         What's this?

The Application of the Principles of Clinical Drug Development to Pharmacological Challenge Tests of the Serotonergic System

South London and Maudsley NHS Trust, London, UK and Centre for Human Drug Research, Department of Clinical Pharmacology, Leiden University, Leiden, The Netherlands harm.gijsman{at}doctors.org.uk

A. F. Cohen

Centre for Human Drug Research, Department of Clinical Pharmacology, Leiden University, Leiden, The Netherlands

J. M. A Van Gerven

Centre for Human Drug Research, Department of Clinical Pharmacology, Leiden University, Leiden, The Netherlands

Pharmacological challenge tests of the serotonergic system have extensively been used during the past 20 years and new tests are in development. It is of crucial importance to standardize challenge tests to ascertain that observed variability is due to the state of the challenged system and not caused by variability of the test itself. This is even more important now that challenge tests increasingly are used in complex studies (e.g. in combination with neuroimaging and in large population studies with repeated tests over time). The Guideline for Good Clinical Practice may be of great help in the standardization of these tests. This is a recently developed guideline for pharmaceutical drug-development, which increasingly is used as a reference for all research in humans. To exemplify the possible usefulness of this approach, we apply it to meta-chlorophenylpiperazine, one of the most commonly used drugs in serotonergic challenge tests. We conclude that much can be learned from the development of this particular challenge. In the discussion, we address general issues that emerged from this review and their relevance to the development of future challenge tests.

Key Words: challenge test • drug development • good clinical practice • mCPP • serotonin

Journal of Psychopharmacology, Vol. 18, No. 1, 7-13 (2004)
DOI: 10.1177/0269881104040205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Strougo, L. Zuurman, C. Roy, J. Pinquier, J. van Gerven, A. Cohen, and R. Schoemaker Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids J Psychopharmacol, September 1, 2008; 22(7): 717 - 726. [Abstract] [PDF]

				L. Smarius, G. Jacobs, D. Hoeberechts-Lefrandt, M. de Kam, J. van der Post, R de Rijk, J van Pelt, R. Schoemaker, F. Zitman, J. van Gerven, et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa J Psychopharmacol, June 1, 2008; 22(4): 426 - 433. [Abstract] [PDF]